New chimeric antigen receptor (car) cells and medical uses thereof
OwnerJuan José LASARTE SAGASTIBELZA, Teresa LOZANO MOREDA +1inventors
InventorsJuan José LASARTE SAGASTIBELZA, Teresa LOZANO MOREDA, Celia MARTÍN OTAL
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new Chimeric Antigen Receptor (CAR) targeting the extra-domain A of fibronectin (EDA), to nucleic acid sequences and vectors encoding thereof, and host cells expressing the same. It further relates to methods of producing thereof, pharmaceutical compositions, kits, methods of treatment, and combination therapies using thereof.
Claims29
A chimeric receptor nucleic acid comprising:
- a) a polynucleotide coding for a ligand binding domain comprising an extra-domain A of fibronectin (EDA) targeting-moiety, wherein the EDA targeting moiety is an antibody fragment comprising:
- i. a VH domain comprising a HCDR1 consisting of SEQ ID NO:
- 1, a HCDR2 consisting of SEQ ID NO:
- 2 and a HCDR3 consisting of SEQ ID NO:
- 3;
- ii. a VL domain comprising a LCDR1 consisting of SEQ ID NO:
- 4, a LCDR2 consisting of SEQ ID NO:
- 5 and a LCDR3 consisting of SEQ ID NO:
- 6;
- b) a polynucleotide coding for a transmembrane domain;
- and
- c) a polynucleotide coding for an intracellular signaling domain.
(canceled)
A method of treating an EDA-positive cancer in a subject wherein said method comprises administering a therapeutically effective amount of a chimeric receptor nucleic acid comprising:
- a) a polynucleotide coding for a ligand binding domain comprising an extra-domain A of fibronectin (EDA) targeting-moiety;
- b) a polynucleotide coding for a transmembrane domain;
- and
- c) a polynucleotide coding for an intracellular signaling domain;
- or
- a chimeric receptor polypeptide coded for thereby;
- an expression vector comprising the chimeric receptor nucleic acid;
- a host cell comprising the chimeric receptor nucleic acid or the expression vector;
- or
- a pharmaceutical composition comprising any thereof and further comprising and a pharmaceutically acceptable excipient, diluent or carrier.
Dependencies are inferred from the claim text.